Welcome to our dedicated page for Surrozen Common news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen Common stock.
Surrozen, Inc. (Nasdaq: SRZN) is a clinical-stage biotechnology firm based in South San Francisco, focused on pioneering regenerative medicine. The company leverages its proprietary technologies to selectively activate the Wnt signaling pathway, a crucial mediator of tissue repair and regeneration. Founded by esteemed scientists from Stanford University, Surrozen aims to unlock the body's self-renewal capabilities through innovative therapeutic approaches.
The company's product pipeline includes several promising candidates:
- SZN-043: Surrozen's lead candidate, SZN-043, uses the company's SWEETS™ technology to treat severe liver diseases, specifically alcohol-associated hepatitis. Following a successful Phase 1a trial that demonstrated safety and target engagement, the company has initiated a Phase 1b clinical trial, with proof-of-concept data anticipated by mid-2025.
- SZN-413: Developed for retinal vascular-associated diseases, SZN-413 leverages Surrozen's SWAP™ technology. Preclinical models have shown that SZN-413 can stimulate Wnt signaling in the eye, potentially inducing normal retinal vessel regrowth. The company has partnered with Boehringer Ingelheim for further research and development, with milestone payments potentially reaching $587.0 million.
Surrozen's strategic direction also includes a strong focus on severe eye diseases and potential applications in other tissues such as the lung and kidney. The company recently published data indicating the potential of Wnt mimetic technologies to treat idiopathic pulmonary fibrosis.
With $43.4 million in cash, cash equivalents, and marketable securities as of September 2023, Surrozen is well-positioned financially to continue its innovative research and clinical trials. The company emphasizes transparency and forward-looking statements, promising continued updates as they advance their clinical programs.
For more details about career opportunities and their latest news, please visit Surrozen's official website.
Surrozen (Nasdaq: SRZN) has announced a $10 million milestone payment from Boehringer Ingelheim as part of their collaboration on retinal diseases. Boehringer is advancing the development of SZN-413, a bi-specific antibody targeting Frizzled Class Receptor 4 (Fzd4) mediated Wnt signaling, designed using Surrozen's SWAP™ technology.
SZN-413 offers the potential to restore retinal function in patients with retinal vascular diseases, which affect nearly 150 million people globally. Preclinical data suggest that SZN-413 could stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.
Craig Parker, President and CEO of Surrozen, expressed excitement about Boehringer's decision to proceed with SZN-413's development, highlighting the strong evidence supporting Fzd-4 specific Wnt signaling's role in retinal vasculature.
Surrozen (Nasdaq: SRZN) reported Q2 2024 financial results and business updates. Key highlights include:
- Ongoing enrollment in SZN-043 Phase 1b trial for Severe Alcoholic Hepatitis
- Presented first-in-human data from SZN-043 Phase 1a trial at EASL
- Published study on Targeted Protein Degradation technologies
- Cash position: $37.8 million as of June 30, 2024
- R&D expenses: $5.3 million, down from $6.9 million in Q2 2023
- Net loss: $25.3 million, up from $9.4 million in Q2 2023
The company anticipates proof-of-concept data from the SZN-043 Phase 1b trial in H1 2025 and potential nomination of a lead Fzd-4 targeted Wnt agonist development candidate in 2024, which could trigger a $10 million milestone payment from Boehringer Ingelheim.
Surrozen (Nasdaq: SRZN) has published new data in eLife demonstrating the potential of its proprietary SWEETS platform to enhance Wnt signaling. The study highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that improve Wnt-signal activation through a unique protein degradation platform. This innovation offers promising new avenues for treating liver diseases by promoting cell-specific regenerative therapeutics. Additionally, Surrozen released a review in iScience detailing advancements in Wnt-activating technologies, underscoring the significant progress in the field and its potential to address various tissue degenerative diseases.
Surrozen presented preliminary Phase 1a study results of their novel drug SZN-043 at the 2024 European Association for the Study of the Liver (EASL) conference in Milan. This study involved 40 healthy volunteers and 8 liver cirrhosis patients, focusing on dose safety and tolerance. SZN-043 showed potential in increasing Wnt signaling and hepatocyte proliferation, with pharmacodynamic biomarkers confirming target engagement. Mild, transient serum transaminase elevations were noted but resolved without intervention. Current enrollment is ongoing for a Phase 1b study targeting severe alcohol-associated hepatitis, aiming to optimize Wnt pathway modulation for liver regeneration.
Surrozen has dosed its first patient in a Phase 1b clinical trial for SZN-043, a bispecific fusion protein targeting ASGR1, aimed at treating severe alcohol-associated hepatitis. This open-label, multi-center trial will involve around 30 patients and assess safety, pharmacokinetics, immunogenicity, and efficacy endpoints like MELD and Lille scores, which are linked to clinical improvement and survival.
CEO Craig Parker highlighted the company's progress and expects proof-of-concept data by the first half of 2025. Previous Phase 1a data indicated SZN-043's safety, tolerability, and beneficial effects on liver function. The trial addresses a significant unmet need, as severe alcohol-associated hepatitis has had no survival improvements for over 50 years.
Surrozen presented data at the ARVO Annual Meeting showcasing the potential of their antibody-based Wnt mimetic technologies in treating cornea endothelial dystrophies and Dry Eye Disease. The preclinical studies demonstrated significant improvements in corneal edema, endothelial cell proliferation, and tear volume production utilizing Surrozen's SWAP technologies. These findings offer hope for patients suffering from these severe eye diseases.
Surrozen, Inc. provided its first quarter 2024 financial results and business updates, focusing on advancing the SZN-043 Phase 1b trial for severe alcohol-associated hepatitis. The company presented promising preclinical data for eye and lung diseases, and highlighted a partnership with Boehringer Ingelheim for retinal disease treatment. Financially, while cash and cash equivalents decreased, a recent financing round boosted proforma cash. Research and development expenses decreased, along with general and administrative expenses, showcasing a strategic focus on clinical programs.
FAQ
What is the current stock price of Surrozen Common (SRZN)?
What is the market cap of Surrozen Common (SRZN)?
What is Surrozen, Inc.?
What is SZN-043?
Who are the founders of Surrozen?
What is SZN-413?
What is the Wnt signaling pathway?
How is Surrozen positioned financially?
What are the potential applications of Surrozen's technologies?
What recent achievements has Surrozen announced?
What should investors know about Surrozen's forward-looking statements?
How can one apply for a career at Surrozen?
